Skip to content

Study · Observational study · n = 47 · 2024

3 results

Cerebrolysin in Patients Diagnosed with Subarachnoid Hemorrhage-The Results of an Observational Cohort Study.

Kojder K, Jarosz K, Andrzejewska A, Solek-Pastuszka J, Skonieczna-Żydecka K, Kaczmarczyk M, Jurczak A

Biomedicines30 Oct 2024

PMID39595058 (opens in a new tab)PMCIDPMC11592139 (opens in a new tab)DOI10.3390/biomedicines12112492 (opens in a new tab)PepBankPUB-39595058
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Background: Subarachnoid hemorrhage (SAH) is associated with high mortality and a high level of disability. Progress in surgical and endovascular techniques has lowered the mortality rate in patients with SAH. However, many patients are left with neurological impairment. Objectives: In our study we wanted to examine the impact of Cerebrolysin on treatment results in patients with SAH diagnosis. Methods: The data of 47 patients, divided into Cerebrolysin (26) and non-Cerebrolysin (21) group were included. We examined the correlation between Cerebrolysin administration and additional Amantadine treatment or neuromonitoring, craniectomy, and endovascular treatment and its impact on the Glasgow Outcome Scale (GOS) score, length of stay (LOS), and mortality. Results: Our study shows that Cerebrolysin improves the mortality rate in combination with neuromonitoring in a group of patients with severe SAH. It does not affect the raw values of GOS or LOS in patients with SAH. Conclusions: Further studies with larger patient groups are needed to investigate the role of Cerebrolysin as an additional treatment in SAH.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with subarachnoid hemorrhage, raw Glasgow Outcome Scale values did not differ between Cerebrolysin and non-Cerebrolysin groups.

    In plain wordsIn patients with brain bleeding, Cerebrolysin was not linked to different Glasgow Outcome Scale values compared with no Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeGlasgow Outcome Scale
    Study

    n = 47

    Comparator
    Non-Cerebrolysin group
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It does not affect the raw values of GOS or LOS in patients with SAH.
    1 context sentence
    Summary · context
    The data of 47 patients, divided into Cerebrolysin (26) and non-Cerebrolysin (21) group were included.
  2. 02HumanObservational studyEfficacy outcome

    In patients with subarachnoid hemorrhage, length of stay did not differ between Cerebrolysin and non-Cerebrolysin groups.

    In plain wordsIn patients with brain bleeding, Cerebrolysin was not linked to a different hospital stay compared with no Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeLength of stay
    Study

    n = 47

    Comparator
    Non-Cerebrolysin group
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It does not affect the raw values of GOS or LOS in patients with SAH.
    1 context sentence
    Summary · context
    The data of 47 patients, divided into Cerebrolysin (26) and non-Cerebrolysin (21) group were included.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 03HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome

    In patients with severe subarachnoid hemorrhage, Cerebrolysin with neuromonitoring was linked to improved mortality.

    In plain wordsIn severe brain bleeding, Cerebrolysin with neuromonitoring was linked to fewer deaths.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseMortality
    Study

    n: not reported in source

    Outcome group
    Mortality · Whole body

    Source sentences

    Summary
    Our study shows that Cerebrolysin improves the mortality rate in combination with neuromonitoring in a group of patients with severe SAH.
    1 context sentence
    Summary · context
    The data of 47 patients, divided into Cerebrolysin (26) and non-Cerebrolysin (21) group were included.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.